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ABSTRACT Chronic exposure of various cell types to
adrenergic agonists leads to a decrease in cell surface P2-
adrenergic receptor (/32AR) number. Sequestration of the
receptor away from the cell surface as well as a down-
regulation of the total number ofcellular receptors are believed
to contribute to this agonist-mediated regulation of receptor
number. However, the molecular mechanisms underlying these
phenomena are not well characterized. Recently, tyrosine
residues located in the cytoplasmic tails of several membrane
receptors, such as the low density lipoprotein and mannose-
6-phosphate receptors, have been suggested as playing an
important role in the agonist-induced internalization of these
receptors. Accordingly, we assessed the potential role of two
tyrosine residues in the carboxyl tail of the human 132AR in
agonist-induced sequestration and down-regulation of the re-
ceptor. Tyr-350 and Tyr-354 of the human f2AR were replaced
with alanine residues by site-directed mutagenesis and both
wild-type and mutant 182AR were stably expressed in trans-
formed Chinese hamster fibroblasts. The mutation dramati-
cally decreased the ability of the f82AR to undergo isoprotere-
nol-induced down-regulation. However, the substitution of
Tyr-350 and Tyr-354 did not affect agonist-induced sequestra-
tion of the receptor. These results suggest that tyrosine residues
in the cytoplasmic tail ofhuman .82AR are crucial determinants
involved in its down-regulation.
perturb the internalization of receptors known to be endocy-
tosed by way of CCVs are also found to perturb the inter-
nalization of the ,82AR. Indeed, the internalization ofboth the
p2AR and the epidermal growth factor receptor is inhibited by
concanavilin A (5), phenylarsine oxide (6), and a reduction in
the cellular ATP content (7). Moreover, high osmolarity or
reduction in intracellular potassium concentration or pH,
which has been shown to interfere with the formation of
clathrin-coated pits (8, 9), is also found to inhibit the inter-
nalization of both the p2AR and the transferrin receptor (31).
In recent studies, tyrosine residues located in the cyto-
plasmic tails of several receptors have been suggested as
molecular determinants that are required for efficient and
rapid agonist-induced CCV-mediated endocytosis. Indeed,
mutation of specific tyrosine residues in the low density
lipoprotein (10), poly-immunoglobulin (11), and mannose-
6-phosphate (12) receptors greatly perturb their internaliza-
tion. Moreover, the insertion of a tyrosine residue in the
cytoplasmic domain of the influenza virus hemagglutinin
promotes the endocytosis of this protein, which normally
does not undergo internalization (13). In the present study,
we have, therefore, assessed the role oftwo tyrosine residues
located in the cytoplasmic tail of the p2AR in agonist-induced
sequestration and down-regulation of the receptor.
Exposure of plasma membrane-bound receptors to agonists
often leads to a rapid decrease ofthe receptor number present
at the surface of the cells. For the 62-adrenergic receptor
(/32AR), this phenomenon is believed to play an important
role in the desensitization of P3-adrenergic responses that
accompanies sustained stimulation (1). Two distinct pro-
cesses appear to contribute to agonist-induced regulation of
cell surface 162AR density (1). The first is a rapid sequestra-
tion of the receptors away from the plasma membrane into a
light vesicle fraction that leads to a reduction in the number
of cell surface receptors but with no change in the total
cellular receptor number. The second is a slower down-
regulation of the receptors that leads to a reduction of the
total cellular contingent of 82AR. Although intracellular
degradation of the receptor has been proposed to contribute
to the down-regulation process (2-4), the molecular mecha-
nisms involved in agonist-induced /82AR sequestration and
down-regulation remain largely unknown.
A growing body of indirect evidence suggests that down-
regulation and/or sequestration of the f82AR may involve its
endocytosis by way of clathrin-coated vesicles (CCVs). This
evidence includes the observation that several factors which
EXPERIMENTAL PROCEDURES
Materials. 1251-labeled iodocyanopindolol, 125I-labeled iodo-
pindolol ([125I]PIN), [a-32P]ATP, and [3H]cAMP were ob-
tained from New England Nuclear. (-)-Isoproterenol (Iso),
(-)-alprenolol, ATP, GTP, cAMP, phosphoenolpyruvate,
myokinase, (-)-propranolol, forskolin, and isobutyl meth-
ylxanthine (IBMX) were purchased from Sigma. Pyruvate
kinase was from Calbiochem. G418, Dulbecco's modified
Eagle's medium (DMEM), fetal bovine serum, fungizone,
glutamine, trypsin, penicillin, Dulbecco's phosphate-buff-
ered saline (PBS), and streptomycin were obtained from
GIBCO. ICI-118551 and betaxolol were generously provided
by Imperial Chemical Industries. CGP-12177 was generously
provided by CIBA-Geigy.
Site-Directed Mutagenesis. A mutant human ,32AR was con-
structed, bearing alanines in place of Tyr-350 and Tyr-354 in
its carboxyl tail ([Ala350,Ala354]/32AR), as follows. The EcoRI-
HindIII fragment ofpSPNAR (14) containing the ,62AR coding
Abbreviations: ,32AR, f2-adrenergic receptor; CCV, clathrin-coated
vesicle; [1251]PIN, '251-labeled iodopindolol; IBMX, isobutylmethyl-
xanthine; Bt2cAMP, N6,02'-dibutyryladenosine 3',5'-cyclic mono-
phosphate; Iso, (-)-isoproterenol; [Ala350,Ala354]I32AR, 832AR with
Tyr-350 and Tyr-354 replaced with alanine; Gs, stimulatory guanine
nucleotide-binding regulatory protein.
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sequence and -40 and -570 base pairs of 5' and 3' untrans-
lated sequence, respectively, was cloned into the EcoRI-
HindIlI sites ofpTZ18R (Pharmacia). Single-stranded DNA of
the noncoding strand was generated using VCS-M13 helper
phage (Stratagene) and served as a template for oligonucle-
otide-directed mutagenesis (Amersham). Identity of the mu-
tant DNA was confirmed by dideoxynucleotide sequencing.
For eukaryotic expression, the EcoRI-HindIII fragment of
[Ala350,Ala354]P2AR DNA in pTZ18R was made blunt-ended
with the Klenow fragment ofDNA polymerase I and cloned
into the blunt-ended HindIII-BamHI sites of pBC12BI (15).
The Nco I site within the simian virus 40 origin in pBC12BI
was cut, blunt-ended as above, and religated prior to inser-
tion of the wild-type and mutant 32AR genes; the vector was
otherwise unaltered. Construction and expression of wild-
type j32AR was as described (16).
Cell Transfection and Culture. Wild-type f32AR and
[Ala350,Ala354182AR pBC12BI constructs were cotransfected
with pSV2-neo (17) into transformed Chinese hamster fibro-
blasts (CHW-1102, hereafter called CHW) by calcium phos-
phate precipitation (18). Neomycin-resistant cells were se-
lected in DMEM supplemented with 10% (vol/vol) fetal
bovine serum and G418 (150 ,ug/ml). Resistant clones were
then screened for f2AR expression in a 125I-labeled iodocy-
anopindolol radioligand binding assay. Cloned cell lines
expressing similar numbers (i.e., -800 fmol/mg ofmembrane
protein) of wild-type and mutant J32AR were selected for
further study. The transfected cells were grown as monolay-
ers in 75-cm2 flasks containing DMEM supplemented with
10%o fetal bovine serum, penicillin (100 units/ml), strepto-
mycin (100 ,g/ml), fungizone (0.25 ,ug/ml), and glutamine (1
mM) in an atmosphere of 95% air/5% CO2 at 37°C.
Agonist-Induced Down-Regulation and Whole-Cell Radio-
ligand Binding Assays. Approximately 90o confluent cells
were incubated at 37°C for various periods of time with
DMEM supplemented as above containing either Iso alone (1
AM) or Iso (1 ,M) plus N6,02'-dibutyryladenosine 3',5'-
cyclic monophosphate (Bt2cAMP) (1 mM) and IBMX (0.1
mM) to prevent Bt2cAMP degradation. Control cells were
incubated with medium alone. After incubation, the cells
were washed twice with PBS, detached with trypsin (0.25%),
washed three times with supplemented DMEM, and resus-
pended in PBS at a concentration of 0.1 mg of protein per ml.
For radioligand binding assays, 50 ,ul of cell suspension was
used with 0.2 ,uCi of [1251]PIN (1 Ci = 37 GBq). Binding
reactions were performed in DMEM at 13°C for 3.5 hr or at
25°C for 1.5 hr in a final volume of 0.5 ml and terminated by
rapid filtration over Whatman GF/C glass fiber filters. Total
receptor number was defined as the amount of radioligand
binding inhibited by 0.3 ,uM (-)-propranolol, whereas cell
surface receptor number was defined as the amount of
[1251]PIN binding inhibited by 0.1 AM CGP-12177.
Membrane Preparations. Cells were washed three times
with 5 ml of PBS at room temperature and mechanically
detached in 10 ml of ice-cold 5 mM Tris-HCI, pH 7.4/2 mM
EDTA. Cells were lysed with a Polytron homogenizer (one
5-sec burst at maximum speed). The lysate was centrifuged
at 45,000 x g for 20 min at 4°C and washed twice in the same
buffer. The pelleted membranes were resuspended in 0.6 ml
of a buffer containing 75 mM Tris HCl, pH 7.4/12.5 mM
MgCl2/2 mM EDTA. For whole-cell and membrane prepa-
rations, protein was measured by the method ofBradford (19)
using bovine serum albumin as standard.
Adenylyl Cyclase Assays. Adenylyl cyclase activities were
measured by the method of Salomon et al. (20). Assay
mixtures contained 0.02 ml of membrane suspension, 0.012
mM ATP, 0.1 mM cAMP, 0.053 mM GTP, 2.7 mM phos-
phoenolpyruvate, 0.2 unit of pyruvate kinase, 1 unit of
myokinase, and 0.13 ,uCi of [a- 2P]ATP in a final volume of
0.05 ml. Enzyme activity was determined in the absence of
activators (i.e., basal activity) or in the presence of 100 ,uM
Iso, 10AM forskolin, or 10mM NaF. Reactions were initiated
by the addition of membranes and the assay mixture incu-
bated for 30 min at 37°C. Reactions were terminated by the
addition of 1 ml of an ice-cold solution containing 0.4 mM
ATP, 0.3 mM cAMP, and [3H]cAMP (=25,000 cpm) and
cAMP was isolated by sequential chromatography on a
Dowex cation-exchange resin and aluminum oxide.
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FIG. 1. Schematic representation of human P2AR. Tyr-350 and Tyr-354 (indicated by arrows) were replaced by alanine residues to generate
a mutant receptor termed [Ala350,Ala35"4'12AR. The single-letter amino acid code is used.
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RESULTS
A mutant human P2AR ([Ala350,Ala354]j 32AR) in which Tyr-
350 and Tyr-354 were replaced by alanine residues was
constructed by oligonucleotide-directed mutagenesis of a
human /82AR cDNA (Fig. 1). CHW cells transfected with
[Ala350,Ala354],B2AR DNA stably expressed a functional re-
ceptor at their plasma membrane. The affinity of this mutated
receptor for the S-adrenergic antagonists 1251-labeled cyan-
opindolol, (-)-alprenolol, ICI-118551, and betaxolol was
indistinguishable from that of wild-type 182AR (data not
shown). Cloned cell lines expressing similar numbers (-800
fmol/mg of membrane protein) of wild-type and mutant
receptors were selected for the study. The cellular distribu-
tion of the expressed receptor was not affected by the
mutation as the proportion of [1251]PIN binding sites present
at the cell surface and accessible to the hydrophilic antagonist
CGP-12177 was identical for wild-type and mutant receptors
(78.3% ± 2.8% vs. 78.3% ± 1.2%).
Exposure of the CHW cells expressing either the wild-type
,82AR or [Ala351,Ala354]132AR to the f3-adrenergic agonist Iso
(1 jzM) led to a rapid and time-dependent reduction in the
number of [125I]PIN binding sites accessible to the hydro-
philic antagonist CGP-12177. As shown in Fig. 2 Inset, this
agonist treatment induces the sequestration of 35% of the
total receptor number away from the cell surface, within 15
min, for both wild-type /32AR and [Ala350,Ala354]f32AR. Thus,
replacement of Tyr-350 and Tyr-354 of the ,2AR with alanine
did not alter the pattern of agonist-induced sequestration in
CHW cells. However, the time-dependent down-regulation
of the total number of 182AR induced by more prolonged
exposure of the cells to Iso was significantly affected by the
mutation. The decrease in specific [125I]PIN binding sites was
significantly slower and reached a maximum of only a 52 ±
3% decrease in cells expressing [Ala350,Ala354],32AR com-
pared with an 81 ± 4% decrease in cells expressing wild-type
p2AR (Fig. 2). It is noteworthy that despite this difference in
down-regulation, the proportion of sequestered receptors
was identical in cells expressing wild-type and mutant recep-
tors even after 24 hr of agonist treatment (data not shown).
Identical results were obtained in two distinct cell lines
expressing [Ala350,Ala354]f32AR, indicating that the impair-
ment in the down-regulation process observed is a conse-
FIG. 2. Iso-induced down-regulation and
sequestration of I82AR in cells expressing
wild-type f32AR and [Ala350,Ala354]i32AR.
Cells were incubated with 1 AuM Iso for 0-24
hr at 370C and whole-cell ,32AR number was
determined by radioligand binding assay us-
ing [1251]PIN as the radioligand. The number
of receptors is expressed as percent of the
receptor number present in untreated cells.
Data are mean ± SEM of three to five
determinations. 0, Wild-type 132AR; o,[Ala350,Ala354]f32AR. (Inset) Sequestration
of 832AR in cells expressing wild-type p2AR
and [Ala350,Ala3541I2AR after incubation
with 1 /LM Iso for 1-15 min. Sequestration is
defined as the difference between the total
receptor number determined by radioligand
binding using [125I]PIN, and the cell surface
receptor number was determined by the
number of sites accessible to the hydrophilic
antagonist CGP-12177. Sequestered recep-
tor number is expressed as percent of total
132AR number. The data shown are repre-
sentative of three experiments. Curves: 1,
wild-type I32AR; 2, [Ala350,Ala354'132AR.
quence of the mutation and not an idiosyncrasy ofa particular
clonal cell line.
When wild-type and mutant receptors were compared in
their abilities to mediate agonist stimulation of adenylyl
cyclase, it was found that the mutation produced a significant
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FIG. 3. Iso- and forskolin-stimulated adenylyl cyclase activity in
cells expressing wild-type 182AR and [Ala350,Ala354]f82AR. Mem-
branes derived from cells expressing wild-type 132AR (open bars) and
from cells expressing [Ala350,Ala354]P2AR (hatched bars) were pre-
pared and stimulated adenylyl cyclase activity was measured. Iso
(0.1 mM) and forskolin (0.1 mM) were used as activators. Adenylyl
cyclase activity is expressed as pmol of cAMP per min per mg of
membrane protein. Data are mean ± SEM (n = 11). Unstimulated
(i.e., basal) adenylyl cyclase activity of cells expressing wild-type
and mutant /82AR was 7.5 ± 1.9 and 6.0 ± 0.5 pmol ofcAMP per min
per mg of membrane protein, respectively.
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depression (50%o) in maximal Iso-stimulated adenylyl cy-
clase activity without altering agonist potency [EC50 for
/32AR = 55 ± 14 nM; EC50 for [Ala350,Ala354]P32AR = 54 + 25
nM (n = 3)] (Fig. 3). The blunted adenylyl cyclase respon-
siveness observed with [Ala350,Ala354]/32AR is unlikely to be
due to an alteration of the adenylyl cyclase catalytic unit in
the mutant cell lines since forskolin-stimulated adenylyl
cyclase activity was identical in cells expressing either wild-
type or mutated receptors (Fig. 3). These findings, therefore,
suggest that the mutation diminished the capacity ofthe P32AR
to efficiently couple with the adenylyl cyclase stimulatory
pathway. This hypothesis is further supported by the obser-
vation that the proportion of 182AR in the high-affinity state
for agonist was significantly lower in cells expressing
[Ala350,Ala354]f32AR than in cells expressing wild-type P32AR[34 ± 7% vs. 63 ± 6% (n = 4)], suggesting that [Ala350,
Ala354],82AR is somewhat uncoupled from the stimulatory
guanine nucleotide-binding regulatory protein (Gs).
We have reported (21) that increased cellular cAMP levels
lead to a down-regulation of f2AR number in CHW cells and
proposed that this mechanism may contribute to the down-
regulation observed upon agonist stimulation of the receptor.
Therefore, to determine whether the impaired coupling abil-
ity of [Ala350,Ala354]132AR and the consequent reduction in
agonist-stimulated cAMP production mediated by the mutant
receptor might be the cause of its altered agonist-induced
down-regulation, the ability of [Ala350,Ala354132AR to un-
dergo Iso-induced down-regulation was tested in the pres-
ence of 1 mM Bt2cAMP and 0.1 mM IBMX. Similar to the
pattern observed for Iso-induced down-regulation of the
mutant (Fig. 2), the down-regulation elicited in the presence
of Bt2cAMP was delayed and blunted in cells expressing
[Ala350,Ala354]82AR compared with wild-type P32AR (Fig. 4).
Moreover, the down-regulation induced by Bt2cAMP alone
was also significantly altered by the mutation (data not
shown). Thus, a lower level of intracellular cAMP accumu-
lation generated by [Ala350,Ala354]fl2AR does not account for
the altered pattern ofdown-regulation ofthe mutant receptor.
DISCUSSION
In the present study, we have shown that mutation ofTyr-350
and Tyr-354 of the ,2AR greatly impairs its ability to undergo
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agonist-induced down-regulation, thus, suggesting that these
residues may be part of a molecular motif involved in the
process regulating total cellular f82AR number. Similarly,
mutations of tyrosine residues located in the carboxyl tails of
the low density lipoprotein (10), poly-immunoglobulin (11),
and mannose-6-phosphate receptors (12) also produce signif-
icant decreases in their rates of agonist-induced internaliza-
tion. The internalization of these receptors has been well
characterized and involves endocytosis by way of CCVs.
More recently, it has been proposed that a tyrosine residue
of the mannose-6-phosphate receptor, mutation of which
causes a dramatic reduction in the internalization process,
may favor the interaction of the receptor with proteins of the
clathrin-coated pit termed "adaptors" (22). Since the loca-
tion of Tyr-350 and Tyr-354 in the carboxyl tail of the ,32AR
(20 and 24 amino acids from the plasma membrane, respec-
tively) is similar to that of the tyrosine residues involved in
the internalization of the mannose-6-phosphate receptor (24
and 26 amino acids from the plasma membrane), it is tempting
to speculate that Tyr-350 and Tyr-354 may contribute in a
similar fashion and promote down-regulation of the receptor
through a CCV-mediated pathway. As indicated above, sev-
eral indirect lines of evidence support a role for clathrin-
coated pits and CCV-mediated endocytosis in the regulation
of cell surface P2AR number. In this context, the involvement
of tyrosine residues in the 182AR down-regulation process
may be taken as additional evidence of the participation of
CCVs in the cellular trafficking of the 182AR.
The possibility that the effects ofthe mutation on the 82AR
down-regulation pattern resulted from a nonspecific confor-
mational change ofthe carboxyl tail of the receptor cannot be
excluded. However, this possibility seems unlikely since
more exhaustive mutations of adjacent regions of the car-
boxyl terminus did not affect the receptor down-regulation.
Indeed, the truncation of the 48 most carboxyl-terminal
amino acids of the receptor (from Leu-413 to Gly-365) (23)
and the replacement of 13 amino acids of the .2AR cytoplas-
mic tail (from Cys-327 to Leu-339) with corresponding resi-
dues from the a2AR (R.J.L., M.B., and P. T. Campbell,
unpublished observation) were found not to modify the
agonist-induced down-regulation of the receptor for up to 12
hr.
FIG. 4. Iso-induced down-
regulation of/82AR in the presence
of Bt2cAMP and IBMX in cells
expressing wild-type /82AR and[Ala350,Ala354])32AR. Cells were
incubated with 1 ,uM Iso, 1 mM
Bt2cAMP, and 0.1 mM IBMX for
0-24 hr at 37°C and whole-cell
P32AR number was determined by
radioligand binding assay using[1251]PIN as the radioligand. The
number of receptors is expressed
as percent of the receptor number
present in untreated cells. Data
are mean + SEM (n = 3). o,20 24 Wild-type 832AR; o, [Ala350,
Ala354iP2AR.
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Classically, two distinct phenomena appear to contribute
to agonist-induced regulation of cell surface 82AR number; a
rapid translocation of the receptor away from the cell surface
to an, as yet, ill-defined light vesicle membrane fraction
(sequestration) and a longer-term loss of total cellular j32AR
(down-regulation). In several studies, down-regulation has
been attributed to degradation of the receptor (2-4). How-
ever, in some cases the recovery of cell surface receptors
after down-regulation has been shown to be rapid and inde-
pendent of de novo protein synthesis (4, 24, 25). This suggests
that a proportion of nondegraded receptors that are unde-
tectable by radioligand binding assay can be recycled back to
the plasma membrane in a fully functional conformation.
Mutation of Tyr-350 and Tyr-354 reduced the extent and
initial rate of agonist-induced down-regulation of the f32AR
without affecting either its rate or extent of sequestration. If
it is assumed that sequestration and down-regulation are
sequential events, these results suggest that Tyr-350 and
Tyr-354 are involved in a mechanism taking place down-
stream of the sequestration process. However, if a distal step
in the sequential pathway was blocked by the mutation, a
change in the proportion of sequestered receptors would be
anticipated. As seen in Fig. 2, this was not the case and the
proportion of sequestered receptor was not affected by the
mutation. Therefore, it appears most likely that mutation of
these tyrosine residues interferes with a down-regulation
mechanism that is independent of the sequestration event.
The existence of such a mechanism is supported by the
observation that atypical partial agonists such as celiprolol or
pindolol can induce down-regulation but not sequestration of
the f2AR (26). Moreover, it has been reported (21) that cAMP
analogues induce down-regulation without sequestration of
the /32AR in CHW cells.
In addition to impairing down-regulation of the P2AR, the
mutation of Tyr-350 and Tyr-354 also affected the coupling of
the receptor to G.. This is indicated by the decreased ability
of the mutated receptor to mediate stimulation of adenylyl
cyclase and to form high-affinity binding with agonist (Fig. 3).
However, the depressed production of cAMP mediated by
[Ala350,Ala354]f32AR does not account for the down-
regulation impairment of the mutant receptor since addition
of high concentrations ofBt2cAMP and IBMX did not restore
a wild-type pattern of down-regulation (Fig. 4). The uncou-
pling of [Ala350,Ala354]J82AR appears to be the consequence of
a decreased ability of the mutated receptor to functionally
interact with Gs and not of a physical sequestration of the
receptor away from the cell surface. Indeed the proportion of
receptor expressed at the cell surface were identical for the
mutated and wild-type receptors.
It, therefore, appears that similar regions of the receptor
might be involved both in Gs coupling and in the process of
receptor down-regulation. In this context, it is noteworthy
that GTP-binding proteins have recently been proposed to
play a role in the endocytotic process (27). Alternatively, the
physical coupling of the receptor to G, might directly con-
tribute to its agonist-induced down-regulation (28-30). How-
ever, the fact that the mutation of tyrosine residues similarly
located in receptors that have no known interactions with G,
also delay receptor internalization (11-13) may argue against
an impairment of G, coupling as the mechanism responsible
for the delayed down-regulation process in these mutants.
In conclusion, as with membrane-bound receptors known
to be endocytosed by way ofCCVs, tyrosine residues located
in the cytoplasmic tail of the human J32AR appear to play an
important role in the regulation of cell surface P2AR number.
These tyrosines may contribute to form a common motif of
noncontiguous amino acids in various classes of transmem-
idues in the /32AR down-regulation process remains to be
clarified.
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